NAS:CTMX (USA) Also trade in: Germany

CytomX Therapeutics Inc

$ 10.14 -0.43 (-4.07%)
Volume: 156,541 Avg Vol (1m): 391,444
Market Cap $: 459.46 Mil Enterprise Value $: 62.86 Mil
P/E (TTM): 0.00 P/B: 3.76
Earnings Power Value -20.14
Net Current Asset Value 1.84
Tangible Book 2.66
Projected FCF 0
Median P/S Value 28.28
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
68.00% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
CTMX: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 2.07, Med: 10000, Max: 10000
Current: 10000
2.07
10000
Equity-to-Asset 0.28
Equity-to-Asset ranked lower than
90.69% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
CTMX: 0.28
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -1.08, Med: 0.29, Max: 0.64
Current: 0.28
-1.08
0.64
Interest Coverage No Debt
Interest Coverage ranked higher than
60.40% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
CTMX: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.37
DISTRESS
GREY
SAFE
Beneish M-Score -0.93
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 4.53%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -105.36
Operating Margin ranked higher than
58.33% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
CTMX: -105.36
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1684.23, Med: -413.32, Max: -64.59
Current: -105.36
-1684.23
-64.59
Net Margin % -111.27
Net Margin ranked higher than
59.09% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
CTMX: -111.27
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1705.29, Med: -425.12, Max: -60.17
Current: -111.27
-1705.29
-60.17
ROE % -82.92
ROE ranked lower than
65.42% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
CTMX: -82.92
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -177.07, Med: -71.19, Max: -57.59
Current: -82.92
-177.07
-57.59
ROA % -19.47
ROA ranked higher than
70.48% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
CTMX: -19.47
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -106.77, Med: -27.95, Max: -14.44
Current: -19.47
-106.77
-14.44
ROC (Joel Greenblatt) % -1317.61
ROC (Joel Greenblatt) ranked lower than
56.76% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
CTMX: -1317.61
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1513.68, Med: -1123.22, Max: -718.79
Current: -1317.61
-1513.68
-718.79
3-Year Total Revenue Growth Rate 97.60
3-Year Revenue Growth Rate ranked higher than
93.86% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
CTMX: 16.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 16.8, Med: 136.9, Max: 155.1
Current: 16.8
16.8
155.1
3-Year Total EBITDA Growth Rate -32.80
3-Year EBITDA Growth Rate ranked higher than
50.25% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
CTMX: 21.5
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -57.7, Med: -13, Max: 21.5
Current: 21.5
-57.7
21.5
3-Year EPS w/o NRI Growth Rate 25.50
3-Year EPS w/o NRI Growth Rate ranked higher than
61.47% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
CTMX: 25.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 14.4, Max: 25.5
Current: 25.5
0
25.5

» CTMX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:CTMX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NYSE:CO NAS:APLS ASX:SRX NAS:ITCI XPAR:ALCLS NYSE:MYOV SZSE:000403 NAS:GTHX NAS:EPZM NAS:DVAX NAS:ARMO NAS:TGTX OCSE:ALK B XPAR:DBV NAS:ASMB SHSE:600645 NAS:WVE NAS:PTCT TSXV:CRON OSTO:HMED
Traded in other countries 6C1.Germany
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities.

Ratios

Current vs industry vs history
PB Ratio 3.76
PB Ratio ranked lower than
94.18% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
CTMX: 3.76
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 3.2, Med: 5.79, Max: 26.52
Current: 3.76
3.2
26.52
PS Ratio 5.85
PS Ratio ranked higher than
52.48% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
CTMX: 5.85
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 5.46, Med: 16.25, Max: 108.04
Current: 5.85
5.46
108.04
EV-to-EBIT -0.82
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
CTMX: -0.82
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -19.8, Med: -5.55, Max: -0.4
Current: -0.82
-19.8
-0.4
EV-to-EBITDA -0.82
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
CTMX: -0.82
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -20.5, Med: -5.7, Max: -0.4
Current: -0.82
-20.5
-0.4
EV-to-Revenue 0.84
EV-to-Revenue ranked higher than
58.88% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
CTMX: 0.84
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.4, Med: 8.85, Max: 86.3
Current: 0.84
0.4
86.3
Current Ratio 4.21
Current Ratio ranked lower than
50.47% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
CTMX: 4.21
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 2.22, Med: 5.55, Max: 12.06
Current: 4.21
2.22
12.06
Quick Ratio 4.21
Quick Ratio ranked higher than
52.79% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
CTMX: 4.21
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 2.22, Med: 5.55, Max: 12.06
Current: 4.21
2.22
12.06
Days Sales Outstanding 0.21
Days Sales Outstanding ranked lower than
78.14% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
CTMX: 0.21
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 0.21, Med: 52.03, Max: 134.8
Current: 0.21
0.21
134.8

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -5.00
3-Year Share Buyback Rate ranked lower than
65.11% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
CTMX: -5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -5, Med: -3.3, Max: -1.5
Current: -5
-5
-1.5

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.81
Price-to-Tangible-Book ranked lower than
91.39% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
CTMX: 3.81
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 3.76, Med: 6.34, Max: 23.3
Current: 3.81
3.76
23.3
Price-to-Median-PS-Value 0.36
Price-to-Median-PS-Value ranked higher than
79.94% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
CTMX: 0.36
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.36, Med: 1.01, Max: 5.78
Current: 0.36
0.36
5.78
Earnings Yield (Joel Greenblatt) % -125.68
Earnings Yield (Greenblatt) ranked higher than
56.61% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
CTMX: -125.68
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -245.8, Med: -18, Max: -5.1
Current: -125.68
-245.8
-5.1

More Statistics

Revenue (TTM) (Mil) $ 74.8
EPS (TTM) $ -1.93
Beta 0.42
Volatility % 51.43
52-Week Range $ 8.94 - 27.2
Shares Outstanding (Mil) 45.31

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N